145 completed, 68 unknown, 61 recruiting, 55 terminated. 212 Phase 2, 128 Phase 1, 45 Phase 3, 24 Not applicable, 4 Phase 4.
Follow Small Cell Lung Cancer: new trials by email Literature Review of Small Cell Lung Cancer trials Research Report on Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| A Phase 1 Study of IM-1340 in Participants With Advanced Cancer IM-1340 - Colorectal Cancer, Non-Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Immunome, Inc. | 200 | 2026-11-01 | 2026-10-22 |
| DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers Obrixtamig, ZL-1310, Atezolizumab - Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Boehringer Ingelheim | 60 | 2026-10-19 | 2026-09-29 |
| Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease Autologous B7-H3 CAR T, Cyclophosphamide, Fludarabine - Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | Phase 1 | Recruiting | National Cancer Institute (NCI) | 40 | 2026-10-16 | 2026-10-21 |
| Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) Tarlatamab - Small Cell Lung Cancer | Phase 3 | Recruiting | Amgen | 400 | 2026-08-28 | 2026-09-17 |
| A Study of Armored CAR T Cells in People With Cancer DLL3-SAVVYZ-IL18 CAR T cell - Neuroendocrine Cancer, Small Cell Lung Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2026-08-28 | 2026-10-22 |
| A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. DXC006, Toripalimab, Carboplatin - Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Hangzhou DAC Biotechnology Co., Ltd. | 200 | 2026-08-19 | 2026-09-24 |
| NK Cells Plus ICI for SCLC Maintenance Allogeneic Natural Killer Cells, Immune Checkpoint Inhibitor - Small Cell Lung Cancer | Phase 2 | Recruiting | Tianjin First Central Hospital | 42 | 2026-08-01 | 2026-08-12 |
| Tarlatamab for SCLC Brain Metastases Tarlatamab - Small Cell Lung Cancer, Brain Metastases, Adult | Phase 2 | Recruiting | Maastricht University Medical Center | 35 | 2026-08-01 | 2026-07-31 |
| QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer QL1706, Anlotinib - Small Cell Lung Cancer | Phase 2 / Phase 3 | Not yet recruiting | Sun Yat-sen University | 120 | 2026-07-30 | 2026-06-09 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer ABBV-706, Topotecan, Lurbinectedin - Small Cell Lung Cancer | Phase 3 | Recruiting | AbbVie | 531 | 2026-07-02 | 2026-09-23 |
| Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer PF-08634404, Chemotherapy - Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ) | Phase 2 | Recruiting | Pfizer | 40 | 2026-07-02 | 2026-10-09 |
| Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy Small Cell Lung Cancer | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 50 | 2026-07-01 | 2026-06-26 | |
| Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression limertinib, etoposide and carboplatin - Small Cell Lung Cancer, Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Hunan Province Tumor Hospital | 30 | 2026-05-01 | 2026-03-16 |
| SMARCA4/2 Inhibitor for POU2F3-Positive SCLC FHD-286 - Small Cell Lung Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 20 | 2026-04-28 | 2026-10-26 |
| 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors 18F-T2 PET/CT - Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC) | Not applicable | Recruiting | Peking University First Hospital | 200 | 2026-04-27 | 2026-05-14 |
| Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer ZG006, Serplulimab - Small Cell Lung Cancer | Phase 1 | Recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 100 | 2026-04-21 | 2026-04-28 |
| Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) ZL-1310, Tarlatamab, Durvalumab - Small Cell Lung Cancer | Phase 1 | Recruiting | Amgen | 160 | 2026-04-21 | 2026-08-21 |
| Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC Albumin-bound Paclitaxel Combined with Local Therapy, Albumin-Bound Paclitaxel /nab-Paclitaxel - Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 84 | 2026-04-06 | 2026-04-23 |
| Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology Blood and Tissue Collection - Small Cell Lung Cancer, Head and Neck Cancer | Not yet recruiting | University of Kansas Medical Center | 110 | 2026-04-01 | 2026-04-24 |
Showing 20 of 388. Sign in to see all of them.
Small Cell Lung Carcinoma (388) · Carcinoma, Non-Small-Cell Lung (71) · Lung Neoplasms (44) · Neoplasms (28) · Ovarian Neoplasms (28) · Breast Neoplasms (24) · Melanoma (20) · Stomach Neoplasms (18) · Uterine Cervical Neoplasms (18) · Carcinoma, Renal Cell (17) · Colorectal Neoplasms (17) · Pancreatic Neoplasms (16) · Sarcoma (16) · Triple Negative Breast Neoplasms (16) · Carcinoma, Hepatocellular (13)
Bronchial Neoplasms (388) · Neoplasms by Site (388) · Respiratory Tract Diseases (388) · Respiratory Tract Neoplasms (388) · Carcinoma, Bronchogenic (387) · Lung Diseases (387) · Thoracic Neoplasms (386) · Neoplasms (360) · Lung Neoplasms (344) · Neoplasms by Histologic Type (74) · Neoplasms, Glandular and Epithelial (58) · Urogenital Diseases (49) · Urogenital Neoplasms (49) · Skin Diseases (46) · Skin and Connective Tissue Diseases (46)
Etoposide (47) · Carboplatin (42) · Cisplatin (38) · Topotecan (30) · Irinotecan (17) · durvalumab (15) · pembrolizumab (15) · Nivolumab (14) · atezolizumab (14) · Paclitaxel (13) · anlotinib (10) · Drug Therapy (9) · Ipilimumab (9) · apatinib (8) · rovalpituzumab tesirine (8)
AbbVie (14) · Amgen (10) · Eli Lilly and Company (8) · Samsung Medical Center (8) · AstraZeneca (5) · Hoffmann-La Roche (5) · National Cancer Institute (NCI) (5) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (5) · Bristol-Myers Squibb (4) · Celgene (4) · Chipscreen Biosciences, Ltd. (4) · Copenhagen University Hospital, Rigshospitalet (4) · G1 Therapeutics, Inc. (4) · H. Lee Moffitt Cancer Center and Research Institute (4) · Memorial Sloan Kettering Cancer Center (4)
United States (168) · China (111) · Spain (49) · South Korea (44) · France (43) · Italy (38) · Belgium (32) · United Kingdom (31) · Germany (29) · Australia (28) · Canada (28) · Poland (27) · Netherlands (26) · Japan (25) · Hungary (20)
Jason Wu (3) · Nasser Hanna, M.D. (3) · Anish Thomas, M.D. (2) · Cesare Gridelli, M.D. (2)
PMID 29290251, PMID 34405547, PMID 34408488, PMID 39113428, PMID 42820295, PMID 32346071, PMID 33595690, PMID 34589918, PMID 36184621, PMID 10080612, PMID 12467231, PMID 12704670, PMID 1310103, PMID 16170339, PMID 16226617, PMID 1648142, PMID 17873178, PMID 18467726, PMID 19096313, PMID 19720897, PMID 19819917, PMID 21102263, PMID 21282543, PMID 21565397, PMID 21633906, PMID 21663862, PMID 22031232, PMID 22722788, PMID 23167406, PMID 23182663, PMID 24124893, PMID 24879333, PMID 25225420, PMID 25616430, PMID 25688059, PMID 25728526, PMID 25903963, PMID 25915780, PMID 25944802, PMID 26106073, PMID 26200278, PMID 26541586, PMID 26640780, PMID 27000274, PMID 27133759, PMID 28097515, PMID 2824710, PMID 28291390, PMID 28548889, PMID 28558150
2016 (7), 2017 (5), 2019 (5), 2023 (5), 2025 (4), 2008 (2), 2014 (2), 2015 (2), 2018 (2), P30CA014089 (2), 2004 (1), 2009 (1), P30CA012197 (1), P30CA015083 (1), R01CA303470 (1)